Nicox Appoints New Chair of the Board and Director
Nicox announced the appointment of the experienced healthcare executive Damian Marron as Chair of the Board of Directors. Marc Le Bozec, an experienced life sciences entrepreneur, was appointed as a new Director of Nicox.
Jean-François Labbe is retiring as chair and member of the board, at the completion of his term. Les Kaplan has also decided to step down from the board.
“I am very pleased to welcome Damian Marron and Marc Le Bozec, who both bring strong and relevant expertise in specific areas of focus for Nicox at this stage of our development. In particular, they will support exploring strategic options and financing opportunities for the company alongside advising on business development discussions on NCX 470 or our other drug candidates,” Gavin Spencer, Chief Executive Officer of Nicox, said in a company news release. “I would like to extend my thanks to Jean-François Labbe and Les Kaplan for their long and dedicated service to Nicox. We have appreciated their experience and guidance as Board members and wish them all the best for the future.”
Mr. Marron is a seasoned executive, four-time CEO, Chair, non-executive Board Member and company advisor with a track record in value creation through public funding, venture capital, portfolio planning, mergers and acquisitions, and license agreements, as well as R&D collaborations. He has experience in both executive and independent administrator roles, with a specialization in immuno-oncology, cellular therapy, and orphan diseases. He is currently chair of the Board of Directors for Circio Holding ASA, Imophoron Ltd, and Indegra Therapeutics Ltd.
Marc Le Bozec is a life sciences entrepreneur with a strong background in finance, organization and strategic consulting. As CFO of Cellectis, he led its IPO in Paris in 2007 and raised €120 million from 2006 to 2013. He then redirected the company Cytoo toward human muscle research, leading to FDA validation and becoming a key shareholder of the company. After 9 years as a professional investor, notably as fund manager at Financière Arbevel, he resumed consulting and also founded Neurodyx in January 2024 to advance neuro-inflammation research.
Nicox's Board of Directors is composed as follows:
- Damian Marron, Chair of the Board and Independent Director
- Gavin Spencer, Chief Executive Officer and Director
- Michele Garufi, Co-Founder and Director
- Marc le Bozec, Independent Director